menu
    • menu

    Company profile for GNT Pharma

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GNT Pharma develops innovative drugs and technology to treat patients who suffer from neurological and inflammatory diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GNT Pharmakorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    1855-23 Yonggudae-ro, Giheung-gu, Yongin-si, Gyeonggi-do, 17096
    Telephone
    Telephone
    031-8005-9910
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://gntpharma.com/en/home_en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GNT Pharma Gets Nod for Ph3 Stroke Trial of Nelonemdaz™Therapy
    GNT Pharma Gets Nod for Ph3 Stroke Trial of Nelonemdaz™Therapy

    24 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gnt-pharma-receives-regulatory-approval-to-initiate-multinational-phase-3-clinical-trials-for-its-breakthrough-stroke-therapy--nelonemdaz--302512910.html

    PR NEWSWIRE
    24 Jul 2025
    Share Share
    GNT Pharma Announces Approval of IND for PIII Trial of Nelonemdaz
    GNT Pharma Announces Approval of IND for PIII Trial of Nelonemdaz

    08 Sep 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/09/08/2293151/0/en/GNT-Pharma-Announces-Approval-of-IND-Application-for-the-Phase-III-RODIN-Trial-of-Nelonemdaz-for-Acute-Ischemic-Stroke-Patients.html

    GLOBENEWSWIRE
    08 Sep 2021
    Share Share
    GNT Eyes Unmet Need As Novel Ischemic Stroke Therapy Moves To Phase III
    GNT Eyes Unmet Need As Novel Ischemic Stroke Therapy Moves To Phase III

    31 Aug 2021

    // Jung Won Shin PHARMA INTELLIGENCE

    https://scrip.pharmaintelligence.informa.com/SC144984/GNT-Eyes-Unmet-Need-As-Novel-Ischemic-Stroke-Therapy-Moves-To-Phase-III

    Jung Won Shin PHARMA INTELLIGENCE
    31 Aug 2021
    Share Share
    GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz
    GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz

    14 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201014005333/en/GNT-Pharma-Announces-Positive-Top-Line-Results-in-a-Phase-II-Study-of-Nelonemdaz-for-Acute-Ischemic-Stroke-Patients-Treated-With-Endovascular-Thrombectomy

    BUSINESSWIRE
    14 Oct 2020
    Share Share
    GNT Pharma Announces Positive Top-Line Results in a Phase II Study
    GNT Pharma Announces Positive Top-Line Results in a Phase II Study

    14 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201014005333/en

    BUSINESSWIRE
    14 Oct 2020
    Share Share
    GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz
    GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz

    14 Oct 2020

    // AFP

    https://www.afp.com/en/news/1314/gnt-pharma-announces-positive-top-line-results-phase-ii-study-nelonemdaz-acute-ischemic-stroke-patients-treated-endovascular-thrombectomy-202010140053331

    AFP
    14 Oct 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search